The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benzodiazepine use is common among patients in opioid agonist therapy; this puts patients at an increased risk of overdose and death. In this study, we examine the impact of baseline and ongoing benzodiazepine use, and whether patients are more likely to terminate treatment with increasing proportion of benzodiazepine positive urine samples. We also study whether benzodiazepine use differs by geographic location. METHODS: We conducted a retrospective cohort study using anonymized electronic medical records from 58 clinics offering opioid agonist therapy in Ontario. One-year treatment retention was the primary outcome of interest and was measured for patients who did and did not have a benzodiazepine positive urine sample in their first month of treatment, and as a function of the proportion of benzodiazepine-positive urine samples throughout treatment. Cox proportional hazard model was used to characterize one-year retention. RESULTS: Our cohort consisted of 3850 patients, with the average retention rate of 43.4%. Baseline benzodiazepine users had a retention rate of 39.9% and non-users had a retention rate of 44%. Patients who were benzodiazepine negative on admission benefited from an increased median days retained of 265 vs. 215 days. Patients with more than 75% of urines positive for benzodiazepines were 175% more likely to drop out of treatment than those patients with little or no benzodiazepine use. CONCLUSIONS: Baseline benzodiazepine use is predictive of decreased retention. Patients who have a higher proportion of benzodiazepine-positive urine samples are more likely to drop out of treatment compared to those who have little or no benzodiazepine detection in their urine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Treatment retention by baseline BZD use. A Cox proportional hazard analysis was used to characterize the time to treatment discontinuation between the patient groups. Log-rank comparison of these curves yielded a chi-square value of 2.883 with a non-significant p value of 0.0895. Baseline BZD users were 14.9% more likely to drop out of treatment than baseline non-users [aHR = 1.15(95% CI 1.02–1.29)]](https://figures.cochat.ai/paper-figures/86849758c7d2441c884212639951ae5e/the-impact-of-benzodiazepine-use-in-patients-enrolled-in-opioid-agonist-therapy-figure-1.jpg)
![Fig. 2 Treatment retention by proportion of BZD-positive urine samples. A Cox proportional hazard analysis was used to characterize the time to treatment discontinuation across the four patient groups. Patients with 25–50% of urines BZD-positive were 26.6% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.26 (95% CI 1.02–1.57)]. Patients with 50–75% of urines BZD-positive were 37.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 1.37(95% CI 1.03–1.832)]. Patients with 75–100% of urines BZD positive were 174.4% more likely to drop out of treatment than patients in the 0–25% reference group [aHR = 2.74(95% CI 2.19–3.43)]](https://figures.cochat.ai/paper-figures/a0dbe1867b1e480984528c814d295d76/the-impact-of-benzodiazepine-use-in-patients-enrolled-in-opioid-agonist-therapy-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Since most studies have not found a change in co-morbid alcohol use, cocaine or benzodiazepine use after initiation of opioid maintenance therapy”
From Effects of a trauma-informed mindful recovery program on comorbid pain, anxiety, and substance use during primary care buprenorphine treatment: A proof-of-concept study (2023) · cites this paper as [58]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703 · cited 1×
“It is for this reason that patients are often prescribed BZD to treat their concurrent mental health disorders [37].”
BackgroundPark, T. W., Saitz, R., Ganoczy, D., Ilgen, M. A., & Bohnert, A. S. B. (2015) · BMJ · doi:10.1136/bmj.h2698 · Cited by 579 · cited 1×
“BZD are often prescribed to patients who are receiving opioid agonist therapy (OAT) [7].”
BackgroundDhalla, I. A., Mamdani, M. M., Sivilotti, M. L. A., Kopp, A., Qureshi, O., & Juurlink, D. N. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.090784 · Cited by 438 · cited 3×
“Additionally, patients using BZD while receiving OAT are at increased risk of overdose and death [1, 24], an event that would be captured as premature drop out in our analysis.”
BackgroundNew insights into the role of the GABAA–benzodiazepine receptor in psychiatric disorder
Nutt, D. J., & Malizia, A. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.5.390 · Cited by 339
Rawson, R. A., Huber, A., McCann, M., Shoptaw, S., Farabee, D., Reiber, C., & Ling, W. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.9.817 · Cited by 290 · cited 2×
“There is considerable evidence to suggest that one year treatment retention is correlated with a variety of positive health outcomes, including reduced drug use, relapse, hospitalization, and illegal activity [20, 21].”
BackgroundThe burden of premature opioid‐related mortality
Gomes, T., Mamdani, M. M., Dhalla, I. A., Cornish, S., Paterson, J. M., & Juurlink, D. N. (2014) · Addiction · doi:10.1111/add.12598 · Cited by 159 · cited 2×
“In Ontario, the number of opioid-related deaths increased by an alarming 242% between 1991 and 2010 [2].”
BackgroundMedical and Nonmedical Use of Prescription Opioids Among High School Seniors in the United States
McCabe, S. E. (2012) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2012.85 · Cited by 158 · cited 1×
“A study relying on self-reports of high school students found that opioid use is increasing among adolescence [26]; therefore, it is possible that the opioid-dependent population in Ontario has gotten younger in recent years, compared to the times and locations at which the other studies on BZD use were conducted.”
ResultDepression in methadone maintenance treatment patients: Rate and risk factors
Peles, E., Schreiber, S., Naumovsky, Y., & Adelson, M. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.09.017 · Cited by 154 · cited 1×
“The higher prevalence of BZD use in this population may be explained by the fact that females in OAT suffer from more psychiatric comorbidity than their male counterparts [32, 33].”
BackgroundBenzodiazepine Use and Misuse Among Patients in a Methadone Program
Chen, K. W., Berger, C. C., Forde, D. P., D'Adamo, C., Weintraub, E., & Gandhi, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-90 · Cited by 149 · cited 1×
“6 [10]; median age = 35 [9]; median age = 47 [25]); however, the age distribution in our dataset seems to reflect the opioid dependent population in Ontario at the time of the study.”
BackgroundWhy buprenorphine is so successful in treating opiate addiction in France
Fatseas, M., & Auriacombe, M. (2007) · Current Psychiatry Reports · doi:10.1007/s11920-007-0046-2 · Cited by 144
Research works printed but not linked: 1
- Adamson S, S.R., Sheridan J, New Zealand Addiction Treatment Research Monograph. Research Proceedings from the Cutting Edge Conference, September 2010, 2012.
Cited by
The epidemiology of benzodiazepine misuse: A systematic review*
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.02.033 · Cited by 479
“Benzodiazepine misuse is often even more prevalent among people in treatment for OUD; past-month estimates range from 7– 73%, with a majority (67%) of studies reviewed reporting rates greater than 40% (ApantakuOlajide et al., 2012; Bleich et al., 2002; Darke et al., 1993, 1994b; Eiroa-Orosa et al., 2010; Franklyn et a…”
BackgroundRetention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
“Similar patterns were observed for studies of buprenorphine, with eight of 12 included studies reporting increased retention with age [56, 58, 69, 70, 72, 82, 86, 93], and mixed OST with four of the six included studies reporting consistent effects for age [43, 44, 53, 87].”
BackgroundResultInfluentialMorin, K. A., Eibl, J. K., Gauthier, G. J., Rush, B. R., Mushquash, C. J., Lightfoot, N., & Marsh, D. C. (2020) · Harm Reduction Journal · doi:10.1186/s12954-020-00396-x · Cited by 63
Self-citationPijl, E. M., Alraja, A. A., Duff, E., Cooke, C. A., Dash, S., Nayak, N., Lamoureux, J., Poulin, G., Knight, E., & Fry, B. (2022) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-022-00463-5 · Cited by 69
“Barriers to patient success included polysubstance use, injection drug use, concurrent mental disorders, lack of awareness of services, apathy, fear of being judged or labeled, fear of child apprehension, fear of law enforcement, fear of disappointing others, maladaptive coping, and economic difficulties [3, 19, 53, 5…”
BackgroundThe impact of cannabis use on patients enrolled in opioid agonist therapy in Ontario, Canada
Franklyn, A. M., Eibl, J. K., Gauthier, G. J., & Marsh, D. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187633 · Cited by 50
Self-citation
Metadata
- Authors
- Franklyn, A. M., Eibl, J. K., Gauthier, G., Pellegrini, D., Lightfoot, N. E., & Marsh, D. C.
- Affiliations
- Laurentian University (CA)
- NOSM University (CA)
- Corresponding author
- Marsh, David C.
- Venue
- Harm Reduction Journal
- Published
- 2017-01-26
- Volume
- 14
- Issue
- 1
- Pages
- 15-15
- ISSN
- 1477-7517 (ISSN-L)
- PMC
- PMC5267412
- OpenAlex
- W2582805122
- Cited by
- 39
- References
- 41
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 1 · 2023: 2 · 2022: 7 · 2021: 7 · 2020: 6 · 2019: 2 · 2018: 3 · 2017: 3
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Update notices
- correction (2017-03-28)
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Harm Reduction Journal (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Northern Ontario Academic Medicine Association
- Canadian Observational Cohort Collaboration
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
- Keywords
- benzodiazepine use, opioid substitution therapy, treatment retention, treatment discontinuation, urine drug testing, opioid overdose risk, opioid use disorder
- MeSH terms
- Adult, Benzodiazepines, Female, Humans, Length of Stay, Male, Methadone, Opioid-Related Disorders, Ontario, Patient Dropouts, Retrospective Studies, Rural Population, Cohort Studies, Treatment Outcome, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. https://app.cochat.ai/papers/10.1186/s12954-017-0134-5
- The paper
- Franklyn, A. M., Eibl, J. K., Gauthier, G., Pellegrini, D., Lightfoot, N. E., & Marsh, D. C. (2017). The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. Harm Reduction Journal. https://doi.org/10.1186/s12954-017-0134-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.